The company behind a search agent to assist clinical decision-making – OpenEvidence – has raised an impressive $210 million in a second-round financing that will support the launch of a tool that can ...

CSL has FDA approval for its new drug to prevent hereditary angioedema (HAE) attacks, Andembry, offering a new, first-in-class option for patients with the rare genetic disorder. Factor XIIa inhibitor ...

Danish GLP-1 giant Novo Nordisk announced a restructuring effort today that will cut 9,000 jobs, a little over 11% of its global workforce. The cut comes a little over a month after the start of new ...

Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations, a rare brain cancer mainly affecting young people. The ...

Eisai has won a patent infringement lawsuit brought against Shilpa Medicare that sought to prevent the Indian generic drugmaker from launching a version of its MSD-partnered cancer drug Lenvima in the ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock was ...

A year ago, Iovance was celebrating becoming the first company to win FDA clearance for a cell therapy used to treat a solid tumour. Now, it is cutting staff in the face of sales growth that has not ...

Swedish biotech Camurus is reportedly in talks to acquire its US partner Braeburn Pharma in a deal that would give it full control of their product for treating opioid use disorder (OUD). Various ...

Lundbeck has announced a major change to its commercial strategy, withdrawing from 27 markets and handing day-to-day operations to partner companies. The move – described as a "sharpening" of ...

Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy the company outright for $1.05 billion. Already a giant in the ...

The San Diego biotech has filed a lawsuit against the Japanese drugmaker and its US subsidiary, NS Pharma, claiming that the ...

J&J has developed two therapies aimed at the estimated two-thirds of MDD patients who continue to experience symptoms despite ...